Huber loss

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Dienstag, Mai 14, 2024
Hypersensitivity, New Drug Application, Patient, Creatinine, Ototoxicity, Uric acid, Azotemia, Huber loss, Coma, Anuria, Cerebral edema, Urinary retention, Erythema, NYHA, Furosemide, Heart failure, Ascites, Hepatic encephalopathy, Kidney, Bruise, Shanda, Urine, FDA, Glucose, Trial of the century, GTN, Edema, PDUFA, Chronic kidney disease, Cirrhosis, Change Healthcare, Growth, Research, Diuresis, BUN, Dehydration, Thrombosis, Deafness, Congestion, CO2, Oliguria, Benign prostatic hyperplasia, Organic acid, History, Blood volume, Hypoproteinemia, Embolism, Tinnitus, Pharmaceutical industry

BURLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million for the first quarter of 2024, compared to $2.1 million for the first quarter of 2023.
  • Costs of product revenues were $1.8 million for the first quarter of 2024, compared to $0.6 million for the first quarter of 2023.
  • Research and development expenses were $2.7 million for the first quarter of 2024, compared to $2.1 million for the first quarter of 2023.
  • scPharmaceuticals reported a net loss of $14.1 million for the first quarter of 2024, compared to $11.2 million for the first quarter of 2023.

WNC & Associates Closes $302 Million Affordable Housing Fund Across 16 States

Retrieved on: 
Donnerstag, Mai 9, 2024
Investment, Housing, LIHTC, Huber loss, WNC, Cryptocurrency

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- WNC & Associates (WNC), a family-owned business known as both a pioneer and leader in the affordable housing industry, has closed WNC Institutional Tax Credit Fund 56, L.P. (Fund 56) which includes 24 multi-family properties across 16 states.

Key Points: 
  • IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- WNC & Associates (WNC), a family-owned business known as both a pioneer and leader in the affordable housing industry, has closed WNC Institutional Tax Credit Fund 56, L.P. (Fund 56) which includes 24 multi-family properties across 16 states.
  • Fund 56, a $302 million equity fund that closed in April 2024, is WNC’s largest multi-investor fund to date.
  • “The closing of Fund 56, our biggest Fund to date, is a testament to the incredible developer and investor partnerships that we have fostered at WNC, and we are thankful for these relationships that will bring nearly 2,400 affordable housing units in 16 states to fruition,” said Anand Kannan, President of WNC.
  • Investments in affordable housing through Fund 56 encompassed a mix of 10 new construction properties and 14 preservations, including three rehabilitations of historic properties.

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

Retrieved on: 
Donnerstag, Mai 9, 2024
Psoriatic arthritis, Hyperglycemia, Graves' ophthalmopathy, Abscess, Huber loss, Risk, QW, Hidradenitis suppurativa, Conference, Webcast, Suicidal ideation, Development, MRCP, Disease, Patient, Fungus, LOS, SLRN, Diplopia, FRCP, IL-17A, POC, CAS, Quality of life, Exophthalmos, Behavior, Infection, Pharmaceutical industry

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today provided an update on various corporate milestones.

Key Points: 
  • This Phase 2b/3 trial, designed to be the first of two registrational trials in TED, is planned to be initiated in the second half of 2024.
  • Izokibep in Uveitis (UV): ACELYRIN expects to complete enrollment in the ongoing Phase 2b/3 trial this month and top line data are anticipated by year-end 2024.
  • ACELYRIN expects to report cash, cash equivalents, and short-term marketable securities of $678.5 million at March 31, 2024.
  • Gil Labrucherie, who serves as ACELYRIN’s Chief Financial Officer, has also been named Chief Business Officer in addition to Chief Financial Officer.

Stratosphere Networks Sponsors Anixter Center's Pure Imagination Event

Retrieved on: 
Donnerstag, Mai 9, 2024
Deafblindness, Huber loss, Hard, Disability, Imagination, Pure Imagination, Mental health, CIO, Mental

CHICAGO, May 9, 2024 /PRNewswire-PRWeb/ -- Stratosphere Networks has announced it will sponsor the Anixter Center's annual fundraiser. The Pure Imagination event will take place on Thursday, May 23, from 6 to 9 p.m. at Venue West at 221 N. Paulina St. in Chicago.

Key Points: 
  • Tech advisory firm contributes to annual fundraiser to support disability, mental health services
    CHICAGO, May 9, 2024 /PRNewswire-PRWeb/ -- Stratosphere Networks has announced it will sponsor the Anixter Center's annual fundraiser.
  • The Pure Imagination event will take place on Thursday, May 23, from 6 to 9 p.m. at Venue West at 221 N. Paulina St. in Chicago.
  • "We're very pleased to sponsor the Pure Imagination event," said Kevin Rubin, president and CIO of Stratosphere Networks.
  • To learn more about the Pure Imagination event, donate, or purchase tickets ($225 per person), please visit the Anixter Center's website .

EARPEACE Launches MOTO PRO ADVENTURE EDITION for Motorcycle Safety Awareness Month in May

Retrieved on: 
Dienstag, Mai 7, 2024
Music, Hearing, Risk, NEXX, Huber loss, Motorcycle Safety Foundation, Red Bull, Ear canal, House, Wind, Motorcycling, Noise-induced hearing loss, Noise, Aluminium, NIHL, NPR Music, Personal protective equipment

WASHINGTON, May 7, 2024 /PRNewswire-PRWeb/ -- Today, EARPEACE is announcing the launch of their MOTO PRO ADVENTURE EDITION for the start of Motorcycle Safety Awareness Month to further expand their mission of enhancing the experiences people value most by reducing noise-induced hearing loss (NIHL).

Key Points: 
  • This week, EARPEACE is announcing the launch of their MOTO PRO ADVENTURE EDITION to further expand their mission of enhancing the experiences people value most by reducing noise-induced hearing loss (NIHL).
  • This month and all-year long, the Motorcycle Safety Foundation recommends hearing protection as part of the necessary personal protection gear for motorcyclists.
  • Now with the EARPEACE MOTO PRO ADVENTURE EDITION, riders can hit the open road with EARPEACE's triple-patented Contour™ earplugs.
  • Available in a 27dB PRO filter set, the MOTO PRO ADVENTURE EDITION includes their Contour™ Earplugs in small, medium, and large sizes along with an aluminum carrying case.

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

Retrieved on: 
Mittwoch, April 24, 2024
Urine, Kidney, FDA, Shanda, Embolism, Huber loss, Hepatic encephalopathy, Uric acid, Oliguria, Congestion, Blood volume, Furosemide, Organic acid, Deafness, Erythema, Cerebral edema, Ascites, Tinnitus, History, Thrombosis, Creatinine, NYHA, Dehydration, BUN, Patient, Hypersensitivity, Ototoxicity, Anuria, Glucose, Azotemia, Hypoproteinemia, CO2, Diuresis, Cirrhosis, Chronic kidney disease, Edema, Urinary retention, Bruise, Growth, Benign prostatic hyperplasia, Coma, Heart failure, Pharmaceutical industry

BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector.

Key Points: 
  • The auto-injector is being developed as a complement to the FDA approved On-body Infusor in an effort to provide patients with a subcutaneous injection and prescribers with treatment flexibility.
  • If approved, the Company believes the auto-injector also has the potential to meaningfully reduce manufacturing costs.
  • FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema.
  • The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.

Study: This Brain Training is Effective for Just About Everyone

Retrieved on: 
Dienstag, April 16, 2024
Education, Brain, Huber loss, Risk, NIH, Hearing loss, Cognition, Research, Grammatical mood, Attention, Exercise, Incidence, Medicare, Athlete, Memory, Quality of life, SAN, Nursing

SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- A large, long-term study of different types of brain training found only the training in the brain health app BrainHQ , made by Posit Science , was effective without regard to a study participant’s demographic or health characteristics.

Key Points: 
  • SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- A large, long-term study of different types of brain training found only the training in the brain health app BrainHQ , made by Posit Science , was effective without regard to a study participant’s demographic or health characteristics.
  • The report, published in the journal of Alzheimer’s and Dementia , examined data from 2,788 participants in the NIH-funded, 20-year, Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) Study.
  • The memory training had higher effect among participants with higher education, better self-rated health, and hearing difficulty.
  • The reasoning training had higher effect in people with higher baseline cognition without vision difficulties.

Global Bionic Devices Research Report 2024: Market to Surpass $10.25+ Billion by 2030, Driven by Transformative Impact on Quality of Life in Retaining Mobility and Independence - ResearchAndMarkets.com

Retrieved on: 
Montag, April 29, 2024
General Health, Health, Medical Devices, Conditional sentence, Amputation, WHO, Person, Huber loss, Hearing loss, Disability, Hospital, Bionics, Cardiology, Elective surgery, Growth, Environment, Incidence, Neurology, Disability studies, Consciousness, Dental implant, Crash, Rehabilitation, Ageing, Fixation, Quality of life, Accident, Prevalence, Medical device

The demand for bionic devices has surged in recent times because of their transformative effect on the quality of existence.

Key Points: 
  • The demand for bionic devices has surged in recent times because of their transformative effect on the quality of existence.
  • North America dominated the global bionic devices market in 2023 and is anticipated to lead the market throughout the forecast period.
  • The electronic bionic devices captured a significant share of the global bionic devices market in 2023.
  • It is predicted that the ambulatory surgical centers will capture nearly a quarter share of the total bionic devices market.

InventHelp Inventor Develops Improved Wireless Earbuds (DNV-617)

Retrieved on: 
Freitag, April 12, 2024
Suite, Sale, Multimedia, Huber loss, Human, Student, Risk, Athlete, Mobile phone

My discreet design would also offer an alternative to wearing traditional earbuds that really stand out and get noticed."

Key Points: 
  • My discreet design would also offer an alternative to wearing traditional earbuds that really stand out and get noticed."
  • The patent-pending invention provides an improved design for cordless earbuds.
  • In doing so, it offers high-quality sound, wireless charging, noise cancellation, voice command capabilities, and connectivity to all devices.
  • 22-DNV-617, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

NYU Langone Health's New Optimal Aging Institute to Further Explore the Link Between Vascular Health and Aging

Retrieved on: 
Donnerstag, April 11, 2024
Kidney disease, Mayo Clinic, Protein, Risk, Blood, Research, Doctor of Philosophy, Cognition, NYU, Life, Lung, Biomarker, Sleep, Population health, Vascular disease, NINDS, NYU Langone Health, University of Texas System, Alzheimer's disease, Baylor College of Medicine, Dementia, University of Minnesota, Ageing, SDOH, Johns Hopkins University, Huber loss, NIH, Amnesia, Publication, Tissue, Heart, MIND, Female, Multimorbidity, Clinical trial, University, Bangladesh Technical Education Board, DSM-IV codes, Notifiable disease, Policy, Frailty, MD, ARIC, Atherosclerosis, Disease, Hypertension, Community, Pharmaceutical industry

NEW YORK, April 11, 2024 /PRNewswire/ -- Researchers at the newly-formed Optimal Aging Institute at NYU Langone Health have been awarded $31 million by the National Institutes of Health (NIH) for a diverse, ten university cohort to study how vascular risk factors contribute to dementia and other age-related disorders in those over the age of 85, building upon existing research.

Key Points: 
  • Close integration with partners across NYU Langone Health system, Coresh said, enables the Institute to implement and test interventions with real-world impacts in real-time, advancing practice-changing research to improve outcomes for all.
  • to highlight an important topic at the intersection of vascular health and aging.
  • The event, co-sponsored by NYU Langone's Department of Population Health and the Optimal Aging Institute, will feature six renowned experts in the field and will showcase recent groundbreaking research on how treating hypertension may prevent dementia.
  • The research is supported by The National Heart, Lung, and Blood Institute, a division of the NIH, grant number U01HL096812.